Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage.
Identifieur interne : 000362 ( PubMed/Curation ); précédent : 000361; suivant : 000363Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage.
Auteurs : Stefan Hauser [Allemagne] ; Sebastian Rogenhofer ; Jörg Ellinger ; Timo Strunk ; Stefan C. Müller ; Guido FechnerSource :
- Urologia internationalis [ 1423-0399 ] ; 2012.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Allemagne, Antiagrégants plaquettaires (effets indésirables), Anticoagulants (effets indésirables), Cathétérisme urinaire, Facteurs temps, Humains, Hyperplasie de la prostate (), Hématurie (), Hématurie (étiologie), Hémoglobines (métabolisme), Hémorragie postopératoire (), Hémorragie postopératoire (sang), Hémorragie postopératoire (étiologie), Lasers à solide, Marqueurs biologiques (sang), Miction, Mâle, Perte sanguine peropératoire (), Prostatectomie (), Prostatectomie (effets indésirables), Prostatectomie (instrumentation), Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Thulium, Thérapie laser (effets indésirables), Thérapie laser (instrumentation), Transfusion sanguine, Troubles de l'hémostase et de la coagulation (), Études de faisabilité, Études rétrospectives.
- MESH :
- effets indésirables : Antiagrégants plaquettaires, Anticoagulants, Prostatectomie, Thérapie laser.
- métabolisme : Hémoglobines, Prostatectomie, Thérapie laser.
- sang : Hémorragie postopératoire, Marqueurs biologiques.
- étiologie : Hématurie, Hémorragie postopératoire.
- Adulte d'âge moyen, Allemagne, Cathétérisme urinaire, Facteurs temps, Humains, Hyperplasie de la prostate, Hématurie, Hémorragie postopératoire, Lasers à solide, Miction, Mâle, Perte sanguine peropératoire, Prostatectomie, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Thulium, Transfusion sanguine, Troubles de l'hémostase et de la coagulation, Études de faisabilité, Études rétrospectives.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Anticoagulants (adverse effects), Biomarkers (blood), Blood Coagulation Disorders (complications), Blood Loss, Surgical (prevention & control), Blood Transfusion, Feasibility Studies, Germany, Hematuria (etiology), Hematuria (prevention & control), Hemoglobins (metabolism), Humans, Laser Therapy (adverse effects), Laser Therapy (instrumentation), Lasers, Solid-State, Male, Middle Aged, Platelet Aggregation Inhibitors (adverse effects), Postoperative Hemorrhage (blood), Postoperative Hemorrhage (etiology), Postoperative Hemorrhage (prevention & control), Prostatectomy (adverse effects), Prostatectomy (instrumentation), Prostatectomy (methods), Prostatic Hyperplasia (complications), Prostatic Hyperplasia (surgery), Retrospective Studies, Thulium, Time Factors, Treatment Outcome, Urinary Catheterization, Urination.
- MESH :
- chemical , adverse effects : Anticoagulants, Platelet Aggregation Inhibitors.
- chemical , blood : Biomarkers.
- chemical , metabolism : Hemoglobins.
- geographic : Germany, Thulium.
- adverse effects : Laser Therapy, Prostatectomy.
- blood : Postoperative Hemorrhage.
- complications : Blood Coagulation Disorders, Prostatic Hyperplasia.
- etiology : Hematuria, Postoperative Hemorrhage.
- instrumentation : Laser Therapy, Prostatectomy.
- methods : Prostatectomy.
- prevention & control : Blood Loss, Surgical, Hematuria, Postoperative Hemorrhage.
- surgery : Prostatic Hyperplasia.
- Aged, Aged, 80 and over, Blood Transfusion, Feasibility Studies, Humans, Lasers, Solid-State, Male, Middle Aged, Retrospective Studies, Time Factors, Treatment Outcome, Urinary Catheterization, Urination.
Abstract
To evaluate the feasibility and safety of thulium:yttrium-aluminium-garnet laser vapoenucleation of the prostate (ThuVEP) in patients with chronic anticoagulation and bleeding disorders.
DOI: 10.1159/000336874
PubMed: 22627127
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000362
Links to Exploration step
pubmed:22627127Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage.</title><author><name sortKey="Hauser, Stefan" sort="Hauser, Stefan" uniqKey="Hauser S" first="Stefan" last="Hauser">Stefan Hauser</name><affiliation wicri:level="1"><nlm:affiliation>Klinik und Poliklinik für Urologie, Universitätsklinikum Bonn, Bonn, Germany. Stefan.Hauser@uni-bonn.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Klinik und Poliklinik für Urologie, Universitätsklinikum Bonn, Bonn</wicri:regionArea></affiliation></author><author><name sortKey="Rogenhofer, Sebastian" sort="Rogenhofer, Sebastian" uniqKey="Rogenhofer S" first="Sebastian" last="Rogenhofer">Sebastian Rogenhofer</name></author><author><name sortKey="Ellinger, Jorg" sort="Ellinger, Jorg" uniqKey="Ellinger J" first="Jörg" last="Ellinger">Jörg Ellinger</name></author><author><name sortKey="Strunk, Timo" sort="Strunk, Timo" uniqKey="Strunk T" first="Timo" last="Strunk">Timo Strunk</name></author><author><name sortKey="Muller, Stefan C" sort="Muller, Stefan C" uniqKey="Muller S" first="Stefan C" last="Müller">Stefan C. Müller</name></author><author><name sortKey="Fechner, Guido" sort="Fechner, Guido" uniqKey="Fechner G" first="Guido" last="Fechner">Guido Fechner</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="doi">10.1159/000336874</idno><idno type="RBID">pubmed:22627127</idno><idno type="pmid">22627127</idno><idno type="wicri:Area/PubMed/Corpus">000362</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000362</idno><idno type="wicri:Area/PubMed/Curation">000362</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000362</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage.</title><author><name sortKey="Hauser, Stefan" sort="Hauser, Stefan" uniqKey="Hauser S" first="Stefan" last="Hauser">Stefan Hauser</name><affiliation wicri:level="1"><nlm:affiliation>Klinik und Poliklinik für Urologie, Universitätsklinikum Bonn, Bonn, Germany. Stefan.Hauser@uni-bonn.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Klinik und Poliklinik für Urologie, Universitätsklinikum Bonn, Bonn</wicri:regionArea></affiliation></author><author><name sortKey="Rogenhofer, Sebastian" sort="Rogenhofer, Sebastian" uniqKey="Rogenhofer S" first="Sebastian" last="Rogenhofer">Sebastian Rogenhofer</name></author><author><name sortKey="Ellinger, Jorg" sort="Ellinger, Jorg" uniqKey="Ellinger J" first="Jörg" last="Ellinger">Jörg Ellinger</name></author><author><name sortKey="Strunk, Timo" sort="Strunk, Timo" uniqKey="Strunk T" first="Timo" last="Strunk">Timo Strunk</name></author><author><name sortKey="Muller, Stefan C" sort="Muller, Stefan C" uniqKey="Muller S" first="Stefan C" last="Müller">Stefan C. Müller</name></author><author><name sortKey="Fechner, Guido" sort="Fechner, Guido" uniqKey="Fechner G" first="Guido" last="Fechner">Guido Fechner</name></author></analytic><series><title level="j">Urologia internationalis</title><idno type="eISSN">1423-0399</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Anticoagulants (adverse effects)</term><term>Biomarkers (blood)</term><term>Blood Coagulation Disorders (complications)</term><term>Blood Loss, Surgical (prevention & control)</term><term>Blood Transfusion</term><term>Feasibility Studies</term><term>Germany</term><term>Hematuria (etiology)</term><term>Hematuria (prevention & control)</term><term>Hemoglobins (metabolism)</term><term>Humans</term><term>Laser Therapy (adverse effects)</term><term>Laser Therapy (instrumentation)</term><term>Lasers, Solid-State</term><term>Male</term><term>Middle Aged</term><term>Platelet Aggregation Inhibitors (adverse effects)</term><term>Postoperative Hemorrhage (blood)</term><term>Postoperative Hemorrhage (etiology)</term><term>Postoperative Hemorrhage (prevention & control)</term><term>Prostatectomy (adverse effects)</term><term>Prostatectomy (instrumentation)</term><term>Prostatectomy (methods)</term><term>Prostatic Hyperplasia (complications)</term><term>Prostatic Hyperplasia (surgery)</term><term>Retrospective Studies</term><term>Thulium</term><term>Time Factors</term><term>Treatment Outcome</term><term>Urinary Catheterization</term><term>Urination</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Allemagne</term><term>Antiagrégants plaquettaires (effets indésirables)</term><term>Anticoagulants (effets indésirables)</term><term>Cathétérisme urinaire</term><term>Facteurs temps</term><term>Humains</term><term>Hyperplasie de la prostate ()</term><term>Hématurie ()</term><term>Hématurie (étiologie)</term><term>Hémoglobines (métabolisme)</term><term>Hémorragie postopératoire ()</term><term>Hémorragie postopératoire (sang)</term><term>Hémorragie postopératoire (étiologie)</term><term>Lasers à solide</term><term>Marqueurs biologiques (sang)</term><term>Miction</term><term>Mâle</term><term>Perte sanguine peropératoire ()</term><term>Prostatectomie ()</term><term>Prostatectomie (effets indésirables)</term><term>Prostatectomie (instrumentation)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Thulium</term><term>Thérapie laser (effets indésirables)</term><term>Thérapie laser (instrumentation)</term><term>Transfusion sanguine</term><term>Troubles de l'hémostase et de la coagulation ()</term><term>Études de faisabilité</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticoagulants</term><term>Platelet Aggregation Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Hemoglobins</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term><term>Thulium</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Laser Therapy</term><term>Prostatectomy</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Postoperative Hemorrhage</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Blood Coagulation Disorders</term><term>Prostatic Hyperplasia</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiagrégants plaquettaires</term><term>Anticoagulants</term><term>Prostatectomie</term><term>Thérapie laser</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hematuria</term><term>Postoperative Hemorrhage</term></keywords><keywords scheme="MESH" qualifier="instrumentation" xml:lang="en"><term>Laser Therapy</term><term>Prostatectomy</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Prostatectomy</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Hémoglobines</term><term>Prostatectomie</term><term>Thérapie laser</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Blood Loss, Surgical</term><term>Hematuria</term><term>Postoperative Hemorrhage</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Hémorragie postopératoire</term><term>Marqueurs biologiques</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Prostatic Hyperplasia</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hématurie</term><term>Hémorragie postopératoire</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Blood Transfusion</term><term>Feasibility Studies</term><term>Humans</term><term>Lasers, Solid-State</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Time Factors</term><term>Treatment Outcome</term><term>Urinary Catheterization</term><term>Urination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Allemagne</term><term>Cathétérisme urinaire</term><term>Facteurs temps</term><term>Humains</term><term>Hyperplasie de la prostate</term><term>Hématurie</term><term>Hémorragie postopératoire</term><term>Lasers à solide</term><term>Miction</term><term>Mâle</term><term>Perte sanguine peropératoire</term><term>Prostatectomie</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Thulium</term><term>Transfusion sanguine</term><term>Troubles de l'hémostase et de la coagulation</term><term>Études de faisabilité</term><term>Études rétrospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate the feasibility and safety of thulium:yttrium-aluminium-garnet laser vapoenucleation of the prostate (ThuVEP) in patients with chronic anticoagulation and bleeding disorders.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22627127</PMID><DateCreated><Year>2012</Year><Month>06</Month><Day>19</Day></DateCreated><DateCompleted><Year>2012</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0399</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>4</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Urologia internationalis</Title><ISOAbbreviation>Urol. Int.</ISOAbbreviation></Journal><ArticleTitle>Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage.</ArticleTitle><Pagination><MedlinePgn>390-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000336874</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate the feasibility and safety of thulium:yttrium-aluminium-garnet laser vapoenucleation of the prostate (ThuVEP) in patients with chronic anticoagulation and bleeding disorders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed the clinical data (transfusion rate, hemoglobin changes, residual urine, bleeding complications, complications and residual urine) of patients with chronic anticoagulation and bleeding disorders treated with ThuVEP. Anticoagulation was not paused for surgery.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 39 patients who fulfilled the inclusion criteria (32 with chronic anticoagulation, 3 with bleeding disorder, and 4 with both). Mean preoperative hemoglobin was 12.9 g/l; the postoperative hemoglobin was 11.7 g/l. One patient received a blood transfusion. Mean residual urine was 166 ml preoperatively and 47 ml postoperatively, respectively; spontaneous voiding postoperatively was feasible in 36 patients. During follow-up, 5 patients suffered from gross hematuria, which was treated conservatively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ThuVEP is a safe procedure in patients with therapeutic anticoagulation, bleeding disorders and platelet aggregation inhibitor medication.</AbstractText><CopyrightInformation>Copyright © 2012 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik für Urologie, Universitätsklinikum Bonn, Bonn, Germany. Stefan.Hauser@uni-bonn.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogenhofer</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ellinger</LastName><ForeName>Jörg</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Strunk</LastName><ForeName>Timo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Stefan C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Fechner</LastName><ForeName>Guido</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Studies</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Urol Int</MedlineTA><NlmUniqueID>0417373</NlmUniqueID><ISSNLinking>0042-1138</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>8RKC5ATI4P</RegistryNumber><NameOfSubstance UI="D013932">Thulium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000925">Anticoagulants</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015415">Biomarkers</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001778">Blood Coagulation Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016063">Blood Loss, Surgical</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001803">Blood Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005240">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005858">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006417">Hematuria</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000517">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006454">Hemoglobins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053685">Laser Therapy</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000295">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D053844">Lasers, Solid-State</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010975">Platelet Aggregation Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019106">Postoperative Hemorrhage</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011468">Prostatectomy</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000295">instrumentation</QualifierName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011470">Prostatic Hyperplasia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D013932">Thulium</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014546">Urinary Catheterization</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014554">Urination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2012</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">000336874</ArticleId><ArticleId IdType="doi">10.1159/000336874</ArticleId><ArticleId IdType="pubmed">22627127</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000362 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000362 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= ThuliumV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:22627127
|texte= Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:22627127" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ThuliumV1
| This area was generated with Dilib version V0.6.21. |  |